Table 2.
Basic characteristics of both cohorts.
| Variable | Frequency | Percentage |
|---|---|---|
| Sex | ||
| HD | ||
| Male | 22 | 52.4 |
| Female | 20 | 47.6 |
| HP | ||
| Male | 25 | 59.5 |
| Female | 17 | 40.5 |
| Primary diagnosis | ||
| HD | ||
| Chronic glomerulonephritis | 14 | 34.1 |
| Chronic pyelonephritis | 2 | 4.9 |
| Diabetic nephropathy | 13 | 31.7 |
| Hypertensive nephropathy | 8 | 19.5 |
| Other | 4 | 9.8 |
| HP | ||
| Chronic glomerulonephritis | 16 | 38.1 |
| Chronic pyelonephritis | 2 | 4.8 |
| Diabetic nephropathy | 13 | 31.0 |
| Hypertensive nephropathy | 9 | 21.4 |
| Other | 2 | 4.8 |
| Effectiveness | ||
| HD | ||
| Ineffective | 6 | 14.3 |
| Effective | 25 | 59.5 |
| Markedly effective | 11 | 26.2 |
| HP | ||
| Ineffective | 1 | 2.4 |
| Effective | 23 | 54.8 |
| Markedly effective | 18 | 42.9 |
| Adverse effects | ||
| HD | ||
| No adverse effects | 32 | 76.2 |
| Muscle spasm | 4 | 9.5 |
| Itchy skin | 3 | 7.1 |
| Cardiovascular event | 2 | 4.8 |
| Dysarteriotony | 1 | 2.4 |
| HP | ||
| No adverse effects | 38 | 90.5 |
| Muscle spasm | 3 | 7.1 |
| Itchy skin | 1 | 2.4 |
HD, hemodialysis group; HP, hemodialysis-hemoperfusion group.